AU2003269133A1 - Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug - Google Patents

Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug

Info

Publication number
AU2003269133A1
AU2003269133A1 AU2003269133A AU2003269133A AU2003269133A1 AU 2003269133 A1 AU2003269133 A1 AU 2003269133A1 AU 2003269133 A AU2003269133 A AU 2003269133A AU 2003269133 A AU2003269133 A AU 2003269133A AU 2003269133 A1 AU2003269133 A1 AU 2003269133A1
Authority
AU
Australia
Prior art keywords
cancer
combination treatment
chemotherapeutic drug
vaccine
cancer vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003269133A
Inventor
Vincenzo Cerundolo
Tsung Wen Cheng
Adrian Lewellyn Harris
Ian Francis Hermans
Michael Joachim Palmowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU2003269133A1 publication Critical patent/AU2003269133A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003269133A 2002-09-17 2003-09-16 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug Abandoned AU2003269133A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0221574.7A GB0221574D0 (en) 2002-09-17 2002-09-17 Treatments
GB0221574.7 2002-09-17
PCT/GB2003/003977 WO2004026337A1 (en) 2002-09-17 2003-09-16 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug

Publications (1)

Publication Number Publication Date
AU2003269133A1 true AU2003269133A1 (en) 2004-04-08

Family

ID=9944248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003269133A Abandoned AU2003269133A1 (en) 2002-09-17 2003-09-16 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug

Country Status (5)

Country Link
EP (1) EP1545592A1 (en)
AU (1) AU2003269133A1 (en)
CA (1) CA2499628A1 (en)
GB (1) GB0221574D0 (en)
WO (1) WO2004026337A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
KR101399591B1 (en) 2005-11-02 2014-06-18 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Concurrent chemotherapy and immunotherapy
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
ITRM20110654A1 (en) * 2011-12-07 2013-06-08 Ist Superiore Sanita COMBINATION OF CYCLOPHOSPHAMID AND DENDRITIC CELLS FOR USE IN THE TREATMENT OF CARCINOMA TO THE UTERINE CERVICE.
FR3042121A1 (en) * 2015-10-08 2017-04-14 Jean-Marc Limacher ANTI-TUMOR COMPOSITION
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
AT500647A1 (en) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie USE OF A VACCINATE

Also Published As

Publication number Publication date
CA2499628A1 (en) 2004-04-01
WO2004026337A1 (en) 2004-04-01
GB0221574D0 (en) 2002-10-23
EP1545592A1 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
AU2002341959A1 (en) Drug delivery devices and methods
AU2002952811A0 (en) Hyperbaric therapy capsule
AU2002252152A1 (en) Tissue electroperforation for enhanced drug delivery and sampling
AU2003220317A1 (en) Methods and drug delivery systems for the treatment of orofacial diseases
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
ZA200410229B (en) Administration of therapeutic viruses
AU2003235956A1 (en) Quinazoline derivative and medicine
GB0119012D0 (en) Transdermal delivery of drugs
AU2003269018A1 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
AU2003269133A1 (en) Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2001243515A1 (en) Combination drug therapy
EP1491210A4 (en) Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2002315878A1 (en) Divided packet and medicine divided packet continuous body
AU2003239144A1 (en) Combination of ablation and controlled drug delivery for the tre atment of cancer
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
AU2003280688A1 (en) Combination therapy of peptide vaccination and estramustine treatment
AU2003221274A1 (en) A kind of chinese traditional medicine having efficacy of reducing blood-fat
EP1485077A4 (en) Drug combination therapy
AU2003264474A1 (en) Novel uracil derivatives and medicinal use thereof
AU2002346272A1 (en) A set of chinese medicine for preventing and treating cancer
AU2002366364A1 (en) E2f and cancer therapy
AU2003242790A1 (en) Therapeutic compound against leishmania infection and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase